ClinicalTrials.gov
ClinicalTrials.gov Menu

Magnesium Sulfate Versus Placebo for Tocolysis in PPROM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00463736
Recruitment Status : Terminated (enrollment proceeding too slowly)
First Posted : April 20, 2007
Last Update Posted : August 19, 2016
Sponsor:
Information provided by (Responsible Party):
Lorrie Mason, Regional Obstetrical Consultants

Brief Summary:
Study compares the outcomes of women between 26 and 32 wks gestation with rupture of membranes. Women randomized to receive tocolysis with magnesium sulfate x 48 hrs or placebo of saline IV x 48 hrs. Antibiotics and antenatal steroids given to both groups.

Condition or disease Intervention/treatment Phase
Preterm Premature Rupture of Membranes Drug: Magnesium sulfate Not Applicable

Detailed Description:

The majority of studies of the effectiveness of tocolysis with PPROM were in the 1980s prior to the commmon usage of antenatal steroids and prophylactic maternal antibiotics. In most studies, tocolysis was not attempted prior to the onset of labor in this group of women. The ACOG Practice Bulletin of June 1998 concedes that the recommendation of tocolysis to permit administration of steroids and maternal antibiotics is based primarily upon consensus, not consistent scientific evidence.

The purpose of this study, which will randomize 128 subjects to tocolysis or no tocolysis, is to prospectively assess whether short term (48 hr) tocolysis affords benefit to women and babies between 26 and 32 weeks gestation with PPROM.

Subjects will be enrolled at 1-2 high risk hospitals in Chattanooga and Knoxville. All English and Spanish speaking women 18-45 years with PPROM and cervical dilation <4 will be eligible. Women with suspected intrauterine infection, positive fetal lung maturity, or > 6 hours tocolysis at time of admission will be excluded.

Both groups of women will receive continuous fetal monitoring, antibiotics, and antenatal steroids (if not previously administered). Both groups will be evaluated every 2-4 hours for fetal and maternal well being. Both groups will receive IVF at 125cc/hr, and the treatment group will be loaded with 4 grams of magnesium sulfate and receive maintainence dose of 2 grams/hr x 48 hrs.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Magnesium Sulfate Versus Placebo for Tocolysis in Preterm Premature Rupture of Membranes
Study Start Date : April 2007
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tears

Arm Intervention/treatment
Active Comparator: Magnesium sulfate
x 48 hours IV
Drug: Magnesium sulfate
Placebo Comparator: Normal saline
x 48 hours IV
Drug: Magnesium sulfate



Primary Outcome Measures :
  1. hours of latency to delivery [ Time Frame: 0 hours to > 168 hours ]
    from start of study drug to delivery


Secondary Outcome Measures :
  1. maternal postpartum length of stay [ Time Frame: 0 hours to > 168 hours ]
    from start of study drug to delivery

  2. maternal infection rates [ Time Frame: 0 hours to > 168 hours ]
    from start of study drug to maternal discharge from hospital

  3. neonatal ventilator days [ Time Frame: 0 to 28 days ]
    from delivery to 28 days of life

  4. neonatal early onset infection [ Time Frame: 0 to 28 days ]
    from delivery to 28 days of life

  5. neonatal length of stay [ Time Frame: 0 to 28 days ]
    from delivery to 28 days of life



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • English or Spanish speaking
  • preterm premature rupture of membranes
  • 26 - 32.6 weeks gestation
  • cervical dilation </= 4 cm

Exclusion Criteria:

  • suspected intrauterine or intraamniotic infection
  • > 6 hours of tocolysis prior to admission
  • positive fetal lung maturity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00463736


Locations
United States, Tennessee
Regional Obstetrical Consultants
Chattanooga, Tennessee, United States, 37403
Sponsors and Collaborators
Regional Obstetrical Consultants
Investigators
Principal Investigator: Christian M Briery, MD Regional Obstetrical Consultants; UT Chattanooga OB-GYN Department

Responsible Party: Lorrie Mason, Christian Briery MD, Regional Obstetrical Consultants
ClinicalTrials.gov Identifier: NCT00463736     History of Changes
Other Study ID Numbers: 07-006
First Posted: April 20, 2007    Key Record Dates
Last Update Posted: August 19, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Lorrie Mason, Regional Obstetrical Consultants:
short term tocolysis
preterm premature rupture of membranes

Additional relevant MeSH terms:
Premature Birth
Rupture
Fetal Membranes, Premature Rupture
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Wounds and Injuries
Magnesium Sulfate
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics
Central Nervous System Depressants
Anti-Arrhythmia Agents
Anticonvulsants
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Tocolytic Agents
Reproductive Control Agents